Home › Funds › Venrock Adviser, LLC › VRDN
Venrock Adviser, LLC position in VRDN
OBSIDIAN THERAPEUTICS INC · Health Care
Venrock Adviser, LLC reported holding 3,257,917 shares of VRDN (OBSIDIAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$59.8M, representing 1.81% of its reported portfolio and ranking #11 among its reported holdings. Venrock Adviser, LLC has disclosed VRDN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's VRDN position evolved
Venrock Adviser, LLC first disclosed a stake in VRDN in Q3 2023 at 3,082,622 shares (US$47.3M). The position peaked in Q4 2025 at 3,882,709 shares, worth US$120.8M. Across 12 filings, Venrock Adviser, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 3,257,917 shares valued at US$59.8M — a reduction of -624,792 shares quarter over quarter.. Notable position changes include a 26% increase in Q4 2023 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.08M | $47.29M | New |
| Q4 2023 | 3.88M | $84.56M | Add |
| Q1 2024 | 3.88M | $67.99M | Hold |
| Q2 2024 | 3.88M | $50.51M | Hold |
| Q3 2024 | 3.88M | $88.33M | Hold |
| Q4 2024 | 3.88M | $74.43M | Hold |
| Q1 2025 | 3.88M | $52.34M | Hold |
| Q2 2025 | 3.88M | $54.28M | Hold |
| Q3 2025 | 3.88M | $83.79M | Hold |
| Q4 2025 | 3.88M | $120.83M | Hold |
| Q1 2026 | 3.88M | $75.95M | Hold |
| Q2 2026 | 3.26M | $59.85M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (OBSIDIAN THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Bellevue Group AG 6.73M sh · $123.67M · Q2 2026
- Paradigm Biocapital Advisors LP 6.72M sh · $123.52M · Q2 2026
- Kynam Capital Management, LP 6.45M sh · $118.56M · Q2 2026
- Fairmount Funds Management LLC 5.09M sh · $93.52M · Q2 2026
- Deep Track Capital, LP 3.59M sh · $66.00M · Q2 2026
- Avoro Capital Advisors LLC 2.50M sh · $45.92M · Q2 2026
- Context Capital Management, LLC 40.75M sh · $43.82M · Q2 2026
- BAKER BROS. ADVISORS LP 2.38M sh · $43.78M · Q2 2026
- Caligan Partners LP 2.19M sh · $40.30M · Q2 2026
- Novo Holdings A/S 2.13M sh · $39.22M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.79M sh · $32.93M · Q2 2026
- First Turn Management, LLC 1.67M sh · $30.68M · Q2 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held VRDN?
Venrock Adviser, LLC has disclosed VRDN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Venrock Adviser, LLC's current position in VRDN?
As of Q2 2026, Venrock Adviser, LLC holds 3.26M shares of VRDN (OBSIDIAN THERAPEUTICS INC), valued at $59.85M, representing 1.81% of its reported portfolio and ranking #11.
Has Venrock Adviser, LLC been buying or selling VRDN?
In the latest 13F filing (Q2 2026), Venrock Adviser, LLC reduced its position in VRDN. The position peaked in Q4 2025 at 3.88M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.